Omaveloxolone manufacturers
- Omaveloxolone
-
- $38.00
-
2026-05-15
- CAS:1474034-05-3
- Purity: 99.10%
- Supply Ability: 10g
- RTA-408
-
- $1.00
-
2019-12-31
- CAS:1474034-05-3
- Min. Order: 1KG
- Purity: Min98% HPLC
|
| | Omaveloxolone Basic information |
| Product Name: | Omaveloxolone | | Synonyms: | Omaveloxolone;N-(2-Cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide;Nrf1-activator-1;Omaveloxolone (RTA-408);RTA-408;RTA 408;RTA408;CS-1306;Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-;RTA-408(Omaveloxolone) | | CAS: | 1474034-05-3 | | MF: | C33H44F2N2O3 | | MW: | 554.71 | | EINECS: | | | Product Categories: | APIs;Omaveloxolone | | Mol File: | 1474034-05-3.mol |  |
| | Omaveloxolone Chemical Properties |
| Boiling point | 662.0±55.0 °C(Predicted) | | density | 1.19±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | ≥55.5 mg/mL in DMSO; insoluble in H2O; ≥25.05 mg/mL in EtOH | | form | Powder | | pka | 13.71±0.70(Predicted) | | color | White to off-white | | InChIKey | RJCWBNBKOKFWNY-IDPLTSGASA-N | | SMILES | C(N[C@]12[C@@]([C@]3(C(=O)C=C4[C@]5(C)[C@](CC[C@]4([C@@]3(CC1)C)C)([H])[C@](C)(C)C(=O)C(C#N)=C5)[H])([H])C[C@@](C)(C)CC2)(=O)C(F)(F)C |
| | Omaveloxolone Usage And Synthesis |
| Uses | Synthetic triterpenoids, such as RTA 408, are antioxidant inflammation modulator (AIM) that can inhibit tumor cell growth and metastasis via oncogenic signaling pathways. RTA 408 is an anticancer, anti-inflammatory, and antioxidant agent that protects human retinal pigment epithelial cells against H2O2-induced cell injury by activating NF-E2-related factor 2. | | Biological Activity | omaveloxolone (rta-408) is a novel synthetic triterpenoid that binds to kelch-like ech-associated protein 1 (keap1) and attenuate nuclear factor erythroid 2-related factor 2 (nrf2) degradation [1].keap1 is involved in proteasomal degradation of nrf2, thereby maintaining low basal levels of nrf2. binding to keap1 and blocking its ability to promote nrf2 degradation increase newly synthesized nrf2 accumulated in the nucleus where nrf2 increases the expression of antioxidant genes and decreases the expression of pro-inflammatory genes [1].in interferon-γ-stimulated raw 264.7 macrophage cells, low concentrations (≤ 25 nm) of rta-408 activated nrf2 and lowered nitric oxide and pro-inflammatory cytokine levels. at higher concentrations, rta-408 inhibited tumor cell growth, with gi50 of 260 ± 74 nm. meanwhile, rta-408 increased caspase activity in tumor cell lines, but not in normal primary human cells.in mice with radiation-induced dermatitis, topical application of rta-408 (0.01%, 0.1% and 1.0%, q.d.) resulted in dose-dependent improvements in the appearance of skin, with 1.0% rta-408 markedly reducing epidermal and collagen thickening, preventing dermal necrosis, and completely alleviating skin ulcers [2].[1]. probst b l, trevino i, mccauley l, et al. rta 408, a novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity. plos one, 2015, 10(4): e0122942.[2]. reisman s a, lee c y, meyer c j, et al. topical application of the synthetic triterpenoid rta 408 protects mice from radiation-induced dermatitis. radiation research, 2014, 181(5): 512-520. | | in vivo | To determine whether Omaveloxolone (RTA-408) is an effective mitigator of hematopoietic acute radiation syndrome after bone marrow-lethal doses of total-body irradiation (TBI), mice are administered 3 daily injections of 17.5 mg/kg Omaveloxolone beginning 24 h after TBI. Teatment with Omaveloxolone results in the 35 day survival of 100% of 7 Gy (LD40/35) TBI mice (P<0.05) and 60% of 7.5 Gy (LD100/13) TBI mice (P<0.0001)[2]. |
| | Omaveloxolone Preparation Products And Raw materials |
|